hardly on the way up..., page-8

Htx has an American peer which have a similar but not as good ovarian test, this American company has just started selling it's test in the US and has a market cap of $57 mil, if we say the htx ovplex test is superior and is launched in the states then using a similar valuation then htx could be 35- 40 cents, prior to future cap raisings diluting market cap.
I think this sort of price is (whilst a long way from 6.6) probable given the American expansion.
If they could get the ovplex test to greater than 99% specifity then it would most likely qualify as a screening test and that would be blue sky..
Will prob drift a little lower first though, we might be back in the 5 cent range soon, time to buy again!